Attached files
file | filename |
---|---|
EX-10.1 - PROMISSORY NOTE IN THE AMOUNT OF $648,000 DATED MAY 15, 2015 IN FAVOR OF MS. QI. - Yew Bio-Pharm Group, Inc. | f8k051515ex10i_yewbiopharm.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2015
Yew Bio-Pharm Group, Inc.
(Exact name of registrant as specified in its charter)
Nevada | 000-54701 | 26-1579105 | ||
(State or other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
9460 Telstar Avenue, Suite 6 El Monte, California |
91731 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (626)-401-9588
Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Information included in this Form 8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Yew Bio-Pharm Group, Inc. (herein referred to as the “Company” or “Registrant”), to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. The Company’s actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.
Section 1-Registrant’s Business and Operations
Item 1.01 | Entry into a Material Definitive Agreement. |
See Item 2.03 below, incorporated by reference herein.
Section 2- Financial Information
Item 2.03 | Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
On May 15, 2015, Ms. Guifang Qi (“Ms. Qi”), a director and Secretary of the Company loaned $648,000 to the Company and the Company executed a Promissory Note (the “Note”) in favor of Ms. Qi. The proceeds of the Note will be used to pay capital expenses and in particular yew extract inventory. Pursuant to the terms of the Note, this loan carries interest of 2% per annum and is payable on November 15, 2015. There is no penalty for early repayment of the Note and the outstanding balance of the Note is immediately due and payable without notice or demand upon, or at any time after, the occurrence or existence of any one or more of the listed “Events of Default”.
A copy of the Promissory Note is attached to this Report as Exhibit 10.1.
Item 9.01. | Exhibits. |
(a) | Exhibits. |
Exhibit | Item | |
10.1 | Promissory Note in the amount of $648,000 dated May 15, 2015 in favor of Ms. Qi. | |
Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.
Yew Bio-Pharm Group, Inc. | ||
Date: May 18, 2015 | By: | /s/ Zhiguo Wang |
Zhiguo Wang, President & CEO |